title: Effect of omeprazole paste on gastric acid secretion in horses.
abstract: In a multicentre trial, 13 cannulated horses were treated orally once daily with a paste that delivered omeprazole at a dose of 4 and 5 mg/kg bwt in a 2-period crossover design to evaluate steady state gastric acid suppression. In each period, basal (unstimulated) and pentagastrin-stimulated gastric output were evaluated at 5-8 h after 5 doses, at 13-16 h after 10 doses, and at 21-24 h after 15 doses. Baseline data for gastric acid secretion were collected once for each horse in the month prior to initiation of omeprazole treatment. The inhibition of gastric acid secretion relative to baseline values, following treatment with omeprazole, were calculated and expressed as per cent. Pharmacokinetic data were also collected in this trial. At 4 mg/kg bwt, the oral paste formulation of omeprazole inhibited both basal and pentagastrin-stimulated gastric acid secretion by 99% at 5-8 h after treatment and by 83% (basal) and 90% (pentagastrin-stimulated) at 21-24 h. Inhibition following the administration of omeprazole at a dose of 5 mg/kg bwt was not significantly greater than when given at 4 mg/kg bwt. The results from this study could possibly lead to the development of an effective and practical antisecretory treatment of ulcer disease in horses.
authors.affiliation: Merial Limited, Iselin, New Jersey 08830-3077, USA.
authors.forename: C P
authors.initials: CP
authors.lastname: Daurio
authors.forename: J E
authors.initials: JE
authors.lastname: Holste
authors.forename: F M
authors.initials: FM
authors.lastname: Andrews
authors.forename: A M
authors.initials: AM
authors.lastname: Merritt
authors.forename: J T
authors.initials: JT
authors.lastname: Blackford
authors.forename: F
authors.initials: F
authors.lastname: Dolz
authors.forename: D R
authors.initials: DR
authors.lastname: Thompson
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D018592:Cross-Over Studies; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D005431:Florida; D005744:Gastric Acid / Q000378:metabolism*; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006736:Horses / Q000378:metabolism*; D007441:Intubation, Gastrointestinal / Q000662:veterinary; D008297:Male; D009515:New Jersey; D009824:Ointments; D009853:Omeprazole / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D010418:Pentagastrin / Q000494:pharmacology; D054328:Proton Pump Inhibitors; D013714:Tennessee
chemical_list: D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D009824:Ointments; D054328:Proton Pump Inhibitors; D010418:Pentagastrin; D009853:Omeprazole